Active Ingredient History

  • Now
Canertinib (CI-1033) is an experimental drug candidate for the treatment of cancer. It is an irreversible tyrosine-kinase inhibitor with activity against EGFR (IC50 0.8 nM), HER-2 (IC50 19 nM) and ErbB-4 (IC50 7 nM). By 2015, Pfizer had discontinued development of the drug.   Wikipedia

  • SMILES: Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl
  • Mol. Mass: 485.95
  • ALogP: 4.39
  • ChEMBL Molecules:
More Chemistry
canertinib | canertinib dihydrochloride | ci1033 | ci 1033 | ci-1033 | ci 980 | ci-980 | pd-0183805 | pd183805 | pd 183805 | pd-183805 | sn-26606


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue